First line chemotherapy in low risk gestational trophoblastic neoplasia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Alazzam, Mo'iad ^a   Tidy, John ^a   Hancock, Barry W ^b   Osborne, Raymond ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Antineoplastic agents *administration dosage; adverse effects ; Case control studies; Cohort studies; Dactinomycin *administration dosage; adverse effects ; Drug administration schedule; Female; Gestational trophoblastic neoplasms *drug therapy ; Humans; Leucovorin administration dosage ; Methotrexate *administration dosage; Adverse effects ; Pregnancy; Randomized controlled trials as topic; Risk; Vitamin B complex administration dosage

Indexed keywords

DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ALOPECIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEATH; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GEOGRAPHY; HEALTH CARE COST; HEMOPTYSIS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; METHODOLOGY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PREGNANCY COMPLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRAINING; TREATMENT FAILURE; TROPHOBLASTIC TUMOR; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VOMITING;

EID: 70249148550     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007102.pub2     Document Type: Review

References (49)

1. Abrao RA, de Andrade JM, Tiezzi DG, Marana HR, Candido dos Reis FJ, Clagnan WS. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecologic Oncology 2008; Vol.108, issue 1:149-153
2. Gilani MM, Yarandi F, Eftekhar Z, Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Australian and New Zealand Journal of Obstetrics andGynaecology 2005; Vol.45, issue 2:161-164 (Pubitemid 40528565)
3. Kohorn EI. Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. Interna- tional Journal of Gynecological Cancer 1996;6:279-285
4. Arb-aroon Lertkhachonsuk, Somsak Tangtrakul, Nathpong Israngura, SarikapanWilailak. ISSTD. 2007.
5. Osborne R, Filiaci V, Schink J, Mannel R, Provencher D, Alvarez-Secord A, et al. A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008; Vol.108: S2-S31.
6. Smith EB, Weed JC, Jr, Tyrey L, Hammond CB. Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid. American Journal of Obstetrics and Gynecology 1982;144(1):88-92.
7. Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. American Journal of Obstetrics and Gynecology 1985; Vol.152, issue 1:59-62. (Pubitemid 15039809)
8. Fabria Yarandi, Zahra Eftekhar, Hadi Shojaei, Soheyla Kanani, Ali Sharifi, ParvizHanjani. Pulsemethotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2008; Vol.103, issue 1:33-37
9. Berkowitz RS, Goldstein DP. Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Obstetrics and Gynecology 1979; Vol.54, issue 6:725-728 (Pubitemid 10241097)
10. Gleeson NC, Finan MA, Fiorica JV, Robert WS, Hoffman MS, Wilson J. Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. European Journal of Gynaecological Oncology 1993; Vol.14, issue 6: 461-465 (Pubitemid 24056720)
11. Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecologic and Obstetric Investigation 1998; Vol.46, issue 1:5-8.
12. Matsui H, Suzuka K, Yamazawa K, Tanaka N,Mitsuhashi A, Seki K, et al.Relapse rate of patients with low-risk gestational trophoblastic tumour initially treated with single-agent chemotherapy. Gynecologic Oncology 2005; Vol.96, issue 3:616-620 (Pubitemid 40255478)
13. Petrilli ES, Morrow CP. Actinomycin D toxicity in the treatment of trophoblastic disease. Gynecologic Oncology 1980;9:18-22.
14. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. American Journal of Obstetrics and Gynecology 1996; Vol.174, issue 6:1917-1923
15. Ayhan A, Yaper EG, Deren O, Kisnisci H. Remission rates and significance of prognostic factors in gestational trophoblastic tumors. Journal of Reproductive Medicine 1992;37(5):461-465
16. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38(3):1373-1385
17. Bagshawe KD, Dent J, Newlands ES, Begent RH, Rustin GJ. The role of low-dosemethotrexate and folinic acid in gestational trophoblastic tumours (GTT). British Journal of Obstetrics and Gynaecology 1989; 96(7):795-802. (Pubitemid 19186634)
18. Covens A, Fialici VL, Burger RA, Osborne R, Chen MD. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia. Cancer 2006;107(6):1280-1286
19. Common Terminology Criteria for Adverse Events (CTCAE). http/ctep/cancer.gov, 9th August 2006; V3.0.
20. Deeks JJ, Altman DG, Bradburn MJ. Statisticalmethods for examining heterogeneity and combining results fromseveral studies inmetaanalysis. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
22. Elit L, Covens A, Osborne R, Gerulath A, Murphy J, Rosen B, et al.High-dose methotrexate for gestational trophoblastic disease. Gyncologic Oncology 1994;54(3):282-287 (Pubitemid 24301901)
23. Hammond CB, Borchert LG, Tyrey L, Creaman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis.. American Journal of Obstetrics & Gynecology 1973;115(4): 451-457
24. Hancock BW, Tidy JA. Current management of molar pregnancy. Journal of Reproductive Medicine 2002;47(5):347-354
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
26. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated Febuary 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
27. Hitchins RN, Holden L, Newlands ES, Begent RH, Rustin GJ, Bagshawe KD. Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987. European Journal of Cancer and Clinical Oncology 1988;24(6):1041-1046
28. Homeseley HD, Blessing JA, Rettenmaier M, Capizzi RL,Major FJ, Twiggs LB. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstetrics and Gynecology 1988;72 (3):413-418 (Pubitemid 18206769)
29. Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecologic Oncology 1990;39(3):305-308
30. Homesley HD. Development of single-agent chemotherapy regimens for gestational trophoblastic disease. Journal of Reproductive Medicine 1994;39(3):185-192
31. Khan F, Everard J, Ahmed S, Coleman RE, Aitkin M, Hancock BW. Low-risk persistent trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long term effects. British Journal of Cancer 2003;89(12):2197-2201 (Pubitemid 38167999)
32. Kohorn EI, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, et al.Combining the staging systemof the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committeeo the International Society for the Study of Trophoblastic Disease and International Gynecologic Cancer Society. International Journal of Gynecological Cancer 2000;10:84-88 (Pubitemid 30219484)
33. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al.Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. Journal of Clinical Oncology 2002;20(7): 1838-1844
34. Nagan HY. The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. International Journal of Gynecology and Obstetrics 2002;77:285-287
35. Osathanondh R, Goldstein DP, Pastorfide GB. Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975; 36(3):863-866
36. Petrilli ES, Twiggs LB, Blessing JA, Teng NH, Curry S. Single-dose actinomycin-Dtreatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987;60(9):2173-2176 (Pubitemid 17153478)
37. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. American Journal of Obstetrics and Gynaecology 1996;174(6):1917-1923
38. Rose PG, Piver MS. Alternating methotrexate and dactinomycin in nonmetastatic gestational trophoblastic disease. Journal of Surgical Oncology 1989;41(3):148-152 (Pubitemid 19190388)
39. Schlaerth JB, Morrow CP, Nalick RH, Gaddis O, Jr. Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Gyncologic Oncology 1984;19(1):53-56 (Pubitemid 14027477)
40. Smith JP. Chemotherapy in gynecologic cancer. Clinical Obstetrics and Gynecology 1975;65:113-116
41. Smith HO, Kim SJ. Epidemiology. In: Hancock BW, Newlands ES, Berkwitz RS, Cole LA editor(s). Gestational Trophoblastic Diseases. 2nd Edition. Internationa Society for the Study of Trophoblastic Diseases, 2003:39-76.
42. Song HZ, Yang XY, Xiang Y. Forty-five year's experience of the treatment of choriocarcinoma and invasivemole. International Journal of Gynaecology and Obstetrics 1998;60 Suppl 1:S77-83.
43. Su WH, Wang PH, Chang SP. Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate. European Journal of Gynaecological Oncology 2001;22(4):283-286
44. Sung HC, Wu PC, Wang YB. Re-evaluation of 5-fluorouracil as a single agent for gestational malignant trophoblastic neoplasms. Advances in Experimental Medicine and Biology 1984;176:355-367
45. Twiggs LB. Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: cost-effective chemotherapy. Gynecologic Oncology 1983;16(2):190-195
46. Wang Y, Jiu L, Guan Y, Qiu D. Chemotherapy using 5-fluorouracil and nitrocaphanum in malignant trophoblastic tumor. Gynecologic Oncology 1998;71(3):416-419 (Pubitemid 29022329)
47. WHO. Gestatational trophoblastic diseases. WHO Technical report Sens 692 1983.
48. Wong LC, Choo YC, Ma HK. Oral etoposide in gestational trophoblastic disease. Cancer Treatment Reports 1984;68(5):775-777 (Pubitemid 14115205)
49. Wong LC, Choo YC, Ma HK. Primary oral etoposide therapy in gestational trophoblastic disease. An update. Cancer 1986;58(1): 14-17 (Pubitemid 16093096)